UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram

International journal of legal medicine, 2013-05, Vol.127 (3), p.579-586

2013

Volltextzugriff (PDF)

Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients

Acta psychiatrica Scandinavica, 2000-05, Vol.101 (5), p.354-359

2000

Volltextzugriff (PDF)

Cost of depression: effect of adherence and treatment response

European psychiatry, 2006-09, Vol.21 (6), p.349-354

2006

Volltextzugriff (PDF)

Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder

Biological psychiatry (1969), 2001, Vol.49 (4), p.360-368

2001

Volltextzugriff (PDF)

Short Onset of Action of a Serotonin Reuptake Inhibitor When Used to Reduce Premenstrual Irritability

Neuropsychopharmacology (New York, N.Y.), 2009-02, Vol.34 (3), p.585-592

2009

Volltextzugriff (PDF)

Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality

International clinical psychopharmacology, 2000-09, Vol.15 (5), p.273-278

2000

Volltextzugriff (PDF)

Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour

Clinical pharmacokinetics, 2009, Vol.48 (1), p.63-70

2009

Volltextzugriff (PDF)

Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study

International clinical psychopharmacology, 2006-03, Vol.21 (2), p.117-124

2006

Volltextzugriff (PDF)

Therapeutic drug monitoring data on Olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

Therapeutic drug monitoring, 2002-08, Vol.24 (4), p.518-526

2002

Volltextzugriff (PDF)

Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study

Journal of clinical psychopharmacology, 2011-02, Vol.31 (1), p.98-102

2011

Volltextzugriff (PDF)

Therapeutic drug monitoring of racemic citalopram: A 5-year experience in Sweden, 1992-1997

Therapeutic drug monitoring, 2003-04, Vol.25 (2), p.183-191

2003

Volltextzugriff (PDF)

Enantioselective Analysis of Citalopram and Escitalopram in Postmortem Blood Together with Genotyping for CYP2D6 and CYP2C19

Journal of analytical toxicology, 2009-03, Vol.33 (2), p.65-76

2009

Volltextzugriff (PDF)

Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting

Therapeutic drug monitoring, 2002-08, Vol.24 (4), p.545-553

2002

Volltextzugriff (PDF)

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

Journal of clinical psychopharmacology, 1998-10, Vol.18 (5), p.390-398

1998

Volltextzugriff (PDF)

Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study

Therapeutic drug monitoring, 2005-08, Vol.27 (4), p.469-477

2005

Volltextzugriff (PDF)

Serum concentrations of fluoxetine in the clinical treatment setting

Therapeutic drug monitoring, 2001-04, Vol.23 (2), p.139-147

2001

Volltextzugriff (PDF)

Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy

Journal of clinical psychopharmacology, 2000-12, Vol.20 (6), p.645-652

2000

Volltextzugriff (PDF)

Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations

Journal of affective disorders, 2004-11, Vol.82 (3), p.443-446

2004

Volltextzugriff (PDF)

Therapeutic drug monitoring of sertraline : Variability factors as displayed in a clinical setting

Therapeutic drug monitoring, 2000-08, Vol.22 (4), p.446-454

2000

Volltextzugriff (PDF)

Symptoms and signs of severe citalopram overdose

The Lancet (British edition), 1997-05, Vol.349 (9065), p.1602-1602

1997

Volltextzugriff (PDF)

Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression

Human psychopharmacology, 2004-07, Vol.19 (5), p.283-291

2004

Volltextzugriff (PDF)

Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine

Therapeutic drug monitoring, 2003-04, Vol.25 (2), p.174-182

2003

Volltextzugriff (PDF)

Regional brain serotonin receptor changes in portacaval shunted rats

Acta physiologica Scandinavica, 1998-04, Vol.162 (4), p.509-516

1998

Volltextzugriff (PDF)

Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting

Journal of clinical psychopharmacology, 2002-08, Vol.22 (4), p.406-413

2002

Volltextzugriff (PDF)

Bioanalysis of racemic Reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC

Therapeutic drug monitoring, 2001-02, Vol.23 (1), p.27-34

2001

Volltextzugriff (PDF)

1 – 25 von 183

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(150)

Publikationsform

Artikel
(182)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram

Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients

Cost of depression: effect of adherence and treatment response

Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder

Short Onset of Action of a Serotonin Reuptake Inhibitor When Used to Reduce Premenstrual Irritability

Non-compliance with pharmacotherapy of depression is associated with a sensation seeking personality

Steady-State Concentrations of Mirtazapine, N-Desmethylmirtazapine, 8-Hydroxymirtazapine and their Enantiomers in Relation to Cytochrome P450 2D6 Genotype, Age and Smoking Behaviour

Response, remission and relapse in relation to adherence in primary care treatment of depression: a 2-year outcome study

Therapeutic drug monitoring data on Olanzapine and its N-demethyl metabolite in the naturalistic clinical setting

Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study

Therapeutic drug monitoring of racemic citalopram: A 5-year experience in Sweden, 1992-1997

Enantioselective Analysis of Citalopram and Escitalopram in Postmortem Blood Together with Genotyping for CYP2D6 and CYP2C19

Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting

Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle?

Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: a 6-month therapeutic drug monitoring study

Serum concentrations of fluoxetine in the clinical treatment setting

Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy

Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations

Therapeutic drug monitoring of sertraline : Variability factors as displayed in a clinical setting

Symptoms and signs of severe citalopram overdose

Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression

Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine

Regional brain serotonin receptor changes in portacaval shunted rats

Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting

Bioanalysis of racemic Reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC

Aktive Filter

Suchergebnisse filtern